- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02934893
A Study to Evaluate the Effect and Benefit of Diabetes Management Decision Support Software for Blood Glucose Control
A Randomized, Controlled, Open-label, Multi-center Study to Evaluate the Effect and Benefit of Diabetes Management Decision Support Software for Blood Glucose Control
The benefit of drug therapy to persons with diabetes has been well established in clinical trials in terms of reducing cardiovascular risk, microvascular complications and mortality. However, treatment adherence and treatment effectiveness continue to be challenges in diabetes management.
Rimidi Diabetes has developed software algorithms to simulate the effect of anti-diabetic medications on an individual's glucose profile, allowing the clinician and their patient to visualize the anticipated outcome of a medical intervention. Use of this technology should allow for more targeted decision-making by the clinician and should facilitate a shared decision-making process with the PwD who is now privy to the thought process behind their medical management.
The proposed study is designed to test whether adding a decision support capability (Diabetes+Me Rx) that allows for modeling the anticipated effect of medication adjustments leads to improved glycemic control and a perceived benefit by healthcare providers and PwDs.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Recruitment
- Recruitment of persons with diabetes through a community diabetes management center according to inclusion and exclusion criteria below.
- This is a three-armed study. Enrollees will be randomized to continue diabetes care with standard diabetes management in the Medication Management Clinic or the Intervention Group and compared to a matched cohort managed through their primary care physician (PCP) and standard of care.
- The Intervention Group will be standard diabetes management in the Medication Management Clinic plus the use of Diabetes+Me with a connected glucometer.
- Upon recruitment, PwD will be oriented to the Diabetes+Me application and instructed on how to complete a glucose profile and how to enter data into the application. Baseline hemoglobin A1C will be measured.
- Enrollees will complete a brief survey of satisfaction with their diabetes management.
Study visits
- The first study visit will be 2 weeks following enrollment.
- Weight, number of medications, number of medication titrations, the presence of insulin and blood pressure will be measured at each study visit. Frequency of hypoglycemia in the preceding week will be documented at each visit. Adherence to medical prescription to be documented at each visit.
- If the PwD has not entered data into Diabetes+Me this will be done at the beginning of each study visit.
- At the first study visit, the HCP will review the glucose profile from the previous week, identify areas where the PwD is not meeting targets and model adjustments to their medications to achieve the desired anticipated effect. If indicated, a new prescription will be issued and the PwD instructed to collect a new glucose profile the week preceding the next visit.
- The second study visit will occur 5 weeks following the initial visit. The HCP and PwD will review the glucose profile from the previous week, identify areas where the PwD is not meeting targets and model adjustments to their medications to achieve the desired anticipated effect. If indicated, a new prescription will be issued and the PwD instructed to collect a new glucose profile the week preceding the final visit.
The third and final study visit will occur 5 weeks following the second visit. The HCP and PwD will review the glucose profile from the previous week and identify if the PwD is meeting targets.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Unzutreffend
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Physician diagnosis of type 1 or type 2 diabetes
- Glycated hemoglobin > 9% within 3 months
- Age 18-80
- Not currently managed by study clinicians
Exclusion Criteria:
- Pregnant
- Active substance abuse
- Severe hearing or visual impairment
- No internet or email access
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Intervention Group
Patient in standard diabetes management in the Medication Management Clinic plus the use of Diabetes+Me plus connected glucometer
|
referral to medication management clinic from primary care
Use of software and medication modeling tool as add on to medication management standard of care
|
Aktiver Komparator: Standard Diabetes Management
Patient in standard diabetes management in the Medication Management Clinic
|
referral to medication management clinic from primary care
|
Kein Eingriff: Primary Care
Matched cohort managed through their primary care physician (PCP) and standard of care.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Hemoglobin A1C
Zeitfenster: change from baseline to 12 weeks
|
change from baseline to 12 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of hypoglycemic events per week
Zeitfenster: change from 1st week to twelfth week
|
Decrease in frequency of hypoglycemia (# events per week
|
change from 1st week to twelfth week
|
Blood pressure
Zeitfenster: change from baseline to 12 weeks
|
increase in percentage of patients with blood pressure in normotensive range
|
change from baseline to 12 weeks
|
BMI
Zeitfenster: change from baseline to 12 weeks
|
decrease in BMI
|
change from baseline to 12 weeks
|
Healthcare provider satisfaction
Zeitfenster: through study completion, an average of 1 year
|
healthcare provider satisfaction based on scoring of questionnaire
|
through study completion, an average of 1 year
|
A1C target attainment
Zeitfenster: at 12 weeks
|
time to A1c goal attainment
|
at 12 weeks
|
Medication titrations needed
Zeitfenster: 12 weeks
|
number of medication titrations over 12 week period needed to reach A1c goal
|
12 weeks
|
Patient satisfaction questionnaire
Zeitfenster: through patient study completion, an average of 12 weeks
|
questionnaire addresses satisfaction with care and knowledge of diabetes self-management
|
through patient study completion, an average of 12 weeks
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Michael Jardula, MD, Desert Oasis Healthcare
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- RD-DOHC
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Diabetes Mellitus
-
Medical College of WisconsinMedical University of South CarolinaAbgeschlossenDiabetes Mellitus | Typ 2 Diabetes mellitus | Altersdiabetes mellitus | Nicht insulinabhängiger Diabetes mellitus | Nicht insulinabhängiger Diabetes Mellitus, Typ IIVereinigte Staaten
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.AbgeschlossenDiabetes mellitus, Typ 1 | Diabetes Typ 1 | Diabetes Typ1 | Diabetes mellitus Typ 1 | Autoimmundiabetes | Diabetes mellitus, insulinabhängig | Jugenddiabetes | Diabetes, Autoimmun | Insulinabhängiger Diabetes mellitus 1 | Diabetes mellitus, insulinabhängig, 1 | Diabetes mellitus, spröde | Diabetes mellitus... und andere BedingungenVereinigte Staaten
-
Guang NingRekrutierungTyp 2 Diabetes mellitus | Diabetes mellitus Typ1 | Monogenetischer Diabetes | Pankreatogener Diabetes | Medikamenteninduzierter Diabetes mellitus | Andere Formen von Diabetes mellitusChina
-
SanofiAbgeschlossenDiabetes mellitus Typ 1 – Diabetes mellitus Typ 2Ungarn, Russische Föderation, Deutschland, Polen, Japan, Vereinigte Staaten, Finnland
-
Meir Medical CenterAbgeschlossenDiabetes mellitus Typ 2 | Diabetes mellitus, nicht insulinabhängig | Diabetes mellitus, zur oralen hypoglykämischen Behandlung | Diabetes mellitus vom ErwachsenentypIsrael
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCAbgeschlossenTyp 2 Diabetes mellitus | Diabetes mellitus Typ1Vereinigte Staaten
-
Hoffmann-La RocheRoche DiagnosticsAbgeschlossenDiabetes mellitus Typ 2, Diabetes mellitus Typ 1Deutschland
-
Hanmi Pharmaceutical Company LimitedUnbekanntTyp 2 Diabetes mellitus | Diabetes mellitus Typ1Vereinigte Staaten
-
University of California, San FranciscoJuvenile Diabetes Research FoundationAbgeschlossenDiabetes mellitus Typ 1 | Diabetes mellitus, Typ I | Insulinabhängiger Diabetes mellitus 1 | Diabetes mellitus, insulinabhängig, 1 | IDDMVereinigte Staaten, Australien
-
Leiden University Medical CenterAndaluz Health ServiceAbgeschlossenDiabetes Mellitus | Gesundheitsverhalten | Selbstwirksamkeit | Typ 2 Diabetes mellitus | Diabetes mellitus Typ1Niederlande, Spanien
Klinische Studien zur Medication Management Clinic
-
University of PittsburghZurückgezogenMedikamentenhaftung | Nebenwirkung auf das Medikament | Nichteinhaltung von MedikamentenVereinigte Staaten
-
University of WashingtonAmerican Association of Diabetes EducatorsUnbekannt
-
Stephen WhitesideNational Institute of Mental Health (NIMH)Abgeschlossen
-
Mayo ClinicRekrutierung
-
Anjali Raja BeharelleMediService AGAnmeldung auf EinladungHypertonie | MedikamentenhaftungSchweiz
-
Collabree AGUniversity Hospital, Basel, SwitzerlandRekrutierungHypertonie | MedikamentenhaftungSchweiz
-
University of Kansas Medical CenterUniversity of Missouri-Columbia; University of UtahRekrutierung
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); Hamilton Academic Health Sciences...AbgeschlossenHerz-Kreislauf-Erkrankungen | Diabetes MellitusKanada
-
University College CorkSidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Cork University... und andere MitarbeiterAktiv, nicht rekrutierendGebärmutterhalskrebs | Brustkrebs | Endometriumkarzinom | ÜberlebenIrland
-
University of OttawaAbgeschlossenBurnout, Profi | Stress, emotional | WiderstandsfähigkeitKanada